Hans L Hillege (Hans Hillege)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 11

Top Topics

Oral Anticoagulants

Cross Sectional

Breast Cancer Risk

Left Atrial Appendage

Top Venues

European heart journal

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

American journal of respiratory and critical care medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Vicente Artola Arita, Martijn E Van De Lande, Neda Khalilian Ekrami, Bao-Oanh Nguyen, Joost P van Melle, Bastiaan Geelhoed, Ruben R De With, Vanessa Weberndörfer, Ömer Erküner, Hans L Hillege, Dominik K Linz, Hugo Ten Cate, Henri M H Spronk, Tim Koldenhof, Robert G Tieleman, Ulrich Schotten, Harry J G M Crijns, Isabelle C Van Gelder, Michiel Rienstra
Clinical utility of the 4S-AF scheme in predicting progression of atrial fibrillation: data from the RACE V study. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
J Hans DeVries, Alar Irs, Hans L Hillege
The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients. European heart journal (2023)
Remco de Brouwer, Wouter P Te Rijdt, Edgar T Hoorntje, Ahmad Amin, Folkert W. Asselbergs, Moniek G P J Cox, Jeroen F van der Heijden, Hans L Hillege, Jacco C Karper, Belend Mahmoud, Peter van der Meer, Anton Oomen, Anneline S J M Te Riele, Herman H W Silljé, Hanno L Tan, Jan Peter van Tintelen, Dirk J van Veldhuisen, Berend Daan Westenbrink, Ans C P Wiesfeld, Tineke P Willems, Paul A van der Zwaag, Arthur A M Wilde, Rudolf A de Boer, Maarten P van den Berg
A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers. European heart journal (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Meindina G Haarman, Johannes M Douwes, Mark-Jan Ploegstra, Marcus T R Roofthooft, Theresia R Vissia-Kazemier, Hans L Hillege, Rolf M F Berger
The Clinical Value of Proposed Risk Stratification Tools in Pediatric Pulmonary Arterial Hypertension. American journal of respiratory and critical care medicine 200 (10) (2020)